‘Targeted Therapy’ cross journal collection with BMC Medicine, guest edited by Prof. Min Li (University of Oklahoma Health Sciences Center) and Dr. Yanis Boumber.
'Microbiome and Cancer’ cross journal collection with Microbiome and BMC Microbiology, guest edited by Prof. Christopher Staley, Dr. Jacques Ravel and Dr. Sean Devlin.
Virtual reality for 3D histology: multi-scale visualization of organs with interactive feature exploration
Liimatainen et al. used VR for visualization of 3D histology data, creating a novel interface for digital pathology to aid cancer research. Their application enables a novel way for exploration of high-resolution, multidimensional data for biomedical research purposes, and can also be used in teaching and researcher training.
Cancer microcell initiation and determination Simsone et al. show that microcells are not only common to a specific cancer type, but can be found in any tumor type. The study contributes to our understanding of cancer emergence and recurrence.
Targeted Therapies for Cancer
Guest edited by Prof. Min Li and Dr. Yanis Boumber
Open for submissions
Microbiome and Cancer
Guest edited by Christopher Staley, Jacques Ravel, Sean Devlin
Open for submissions
Cross journal collection: Advances in CAR-T immunotherapy
Guest edited by Profs Marko Radic, Djordje Atanackovic and Tim Luetkens
Collection published: 30 June 2020
Cross journal collection: Precision Oncology
Collection published: 28 August 2019
Browse all BMC Cancer collection contributions
MULISARC trial: molecular profiling of advanced soft-tissue sarcomas
THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy
Learn more about study protocols at BMC Cancer here
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials. Learn more about our scope here.
BMC Cancer is celebrating its 20th anniversary!
Since launching in 2001, we've become established as the largest open access oncology journal in our field. We're proud of our history of making cancer research and methods available to all. We have been looking back at our achievements and highlighted some of the most influential research published in the journal over the past two decades.
Dr. Rebersek provides an overview of known features of the gut microbiome and its role in initiation and development of CRCs and explores whether and to what extent racial disparity in CRC is affected by the gut microbiome.
Feature article: Are cancer patients better off if they participate in clinical trials?
How do physicians and nurses perceive the benefits of clinical trial participation compared with standard care? Is it justified to claim that clinical trial participation improves outcomes for cancer patients? Zandra Nielsen et al. present their latest findings of a mixed-methods study in Scandinavia.
Your browser needs to have JavaScript enabled to view this timeline
Citation Impact
4.430 - 2-year Impact Factor
4.372 - 5-year Impact Factor
1.218 - Source Normalized Impact per Paper (SNIP)
1.358 - SCImago Journal Rank (SJR)
Speed
37 days to first decision for all manuscripts
79 days to first decision for reviewed manuscripts only
170 days from submission to acceptance
16 days from acceptance to publication
Usage
6,897,358 Downloads (2021)
2,117 Altmetric Mentions
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication
